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BACKGROUND. BRAFV600E mutation and p27kip1 expression have been introduced
as novel indicators that may predict prognosis in different tumors, as well as in
papillary thyroid carcinomas.
METHODS. Tissue samples from 214 consecutive patients who underwent total or
near-total thyroidectomy with histological diagnosis of papillary thyroid carci-
noma (PTC) 1 cm were analyzed for BRAFV600E mutation by a real-time, allele-
specific amplification and for p27kip1 expression by immunohistochemistry.
RESULTS. The BRAFV600E mutation was detected in 88 of the tumors examined,
with significant differences between groups with and without lymph node (LN)
metastases; the mean age of patients with BRAFV600E mutation was significantly
higher than that of patients without mutations. A significant association was
found between low p27Kip1 protein expression and multifocality, bilaterality, and
extrathyroidal extension, in addition to LN metastasis. In 42 cases with LN me-
tastases, 23 harbored the BRAFV600E mutation in the metastatic tumor and pre-
sented a wider diameter of the largest metastatic area, a higher number of
involved LNs, and a higher percentage of metastatic lesions with extracapsular
extension of LN (ECE-LN). A significantly lower mean value of p27Kip1 was
observed in LNs harboring the BRAFV600E mutation and in ECE-LN; an inverse
correlation was found between p27Kip1 and the number of metastatic LNs, as
well as the diameter of the largest metastatic area in LN.
CONCLUSIONS. The authors’ data suggested that BRAFV600E mutation and p27Kip1
down-regulation in cancer cells of PTC 1 cm may be factors that facilitate
tumor-cell growth and progression once these are seeded in the LNs. Cancer
2007;110:1218–26.  2007 American Cancer Society.
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I t is a well-known fact that papillary thyroid carcinomas (PTC) of-ten comprise relatively small tumors compared with other histo-
logical types of thyroid tumors. In the last few years, it has been
estimated that as the use of thyroid ultrasound and other neck-ima-
ging modalities has increased, nodules that are not large enough to
be palpated are discovered and identified with greater frequency.1,2
Because they are often found in thyroids resected for other lesions,
small PTCs that measure 1.0 cm are often described as ‘‘microcar-
cinoma,’’ ‘‘occult,’’ or ‘‘incidental’’.
Small PTCs usually have an excellent clinical outcome, but their
prognostic factors have not yet been fully established. In a recent
retrospective chart-review study of patients treated and followed for
small (<1.5 cm) papillary thyroid cancers, nonincidental thyroid
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cancer and lymph node (LN) metastases at presenta-
tion were found to be associated with persistent
and/or recurrent disease.3
BRAFV600E mutation and p27kip1 expression have
been introduced as novel indicators that may also
predict a poorer prognosis in various tumors, as well
as in PTC. BRAF is a member of the RAF kinase fam-
ily and promotes signaling through the RAS-MAP ki-
nase signal-transduction cascade.4 Mutations of the
BRAF gene have been found in a variety of human
cancers, most notably in melanomas and thyroid
cancer. The most common BRAF mutation is the
T1799A transversion mutation (formerly known as
BRAF T1796A mutation) in exon 15 of the gene. This
mutation causes a V600E (formerly known as V599E)
amino acid substitution in the protein and confers
the kinase oncogenic function through constitutive
activation of the MAPK signaling pathway.4
The p27Kip1 protein is an important cdk inhibitor
and inhibits the formation of cyclin D1/cdk com-
plexes during G0 and early G1 phases of the cell
cycle, and its decrease is closely related to cell-cycle
progression in many cancers.5
The aim of the present study was to determine
the frequency of BRAFV600E mutation and the expres-
sion of p27Kip1 protein in a series of primary PTCs
1.0 cm and their paired LN metastases.
MATERIALS AND METHODS
Patients
We considered a group of 214 consecutive patients
who underwent total or near-total thyroidectomy
during the period from January 1990 to December
1999, with histological diagnosis of PTC 1 cm, and
who were followed in our endocrinology clinic. This
retrospective study was performed in accordance
with the rules of the institutional review board at the
Faculty of Medicine (University of Palermo). Forty-
two patients had regional LN metastases, 36 with
nonincidental and 6 with incidental carcinomas.
Histopathological Evaluation and Tumor Staging
Tumor specimens stored in the archives of the Insti-
tute of Pathologic Anatomy and Histology of the Uni-
versity of Palermo provided adequate histological
material. For each case, all histological slides were
reviewed by 2 pathologists (V.R. and D.C.), who
were unaware of the clinical data, and diagnoses
were reassessed according to the World Health Orga-
nization classification of thyroid malignancy.6
All primary tumors included in this study were
classified as classical variants of PTC; tumors with
morphological features of the follicular variant of
PTC were not included. Tumors were staged accord-
ing to the sixth edition of the Cancer Staging Man-
ual,7 where T (extent of the primary tumor) and N
(regional LN metastasis) were determined on the ba-
sis of pathological data, and M (evidence of distant
metastasis) was based on findings at the first post-
operative 131I whole-body scan.
All tissue samples were fixed in 10% buffered for-
malin, dehydrated in ethanol, and paraffin-embed-
ded according to the routine technique. Hematoxylin
& eosin-stained sections of 5 lm thickness were reas-
sessed for intraglandular multifocality, bilaterality,
tumor extension beyond the thyroid capsule or extra-
thyroidal invasion, vascular invasion, grade of sclero-
sis (sclerosing or nonsclerosing type) according to
the amount of fibrous stroma coexisting with malig-
nant cells, degree of encapsulation (encapsulated or
nonencapsulated), and maximum diameter of the
primary lesion (<5 mm or 5 mm.). Sections of LN
metastases were reassessed for the number of
involved LNs, extracapsular extension (ECE) of the
metastatic lesion, and diameter of the largest meta-
static area.
Immunohistochemistry
The avidin-biotin peroxidase complex technique was
used on 5 lm sections of formalin-fixed, paraffin-
embedded tissues after deparaffinization as pre-
viously described.8 Briefly, the sections were reacted
consecutively with the monoclonal antibody K25020
(Transduction Laboratories, Lexington, Ky) generated
from mouse p27Kip1 protein at a concentration of
1:200. Thereafter, slides were washed in phosphate-
buffered saline (PBS), and secondary incubations
were carried out by using biotinylated alpha mouse
IgG obtained from horse serum (ABC Kit; Vector Lab-
oratories, Burlingame, Calif) for 30 minutes. Finally,
3,3-diaminobenzidine tetrahydrochloride (Dako,
Glostrup, Denmark) in distilled water was used as
the chromogen for 10 minutes, and sections were
counterstained with Mayer hematoxylin.
The p27Kip1 protein expression in each tumor
and matched LN metastases was evaluated according
to its intensity. p27Kip1 expression was positive if the
staining intensity of tumor cell nuclei was equal to
or stronger than that of the adjacent lymphocytes
and negative otherwise.9–11 The staining of p27Kip1
protein in each tumor and matched LN metastases
was evaluated under high-powered fields (final mag-
nification, 3400) and reported as the percentage of
expressor cells among the total number of counted
cancer cells and used as a labeling index (LI). For
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multifocal tumors and multiple LN metastases, the
evaluations were assessed on different areas of all
lesions. Twenty cases were evaluated separately by 2
different pathologists (D.C. and A.M.); because the
variation was less than 5%, the first pathologist’s data
were used. Based on the median value (24.8%; range,
0%–90.1%) of p27Kip1 protein expression in primary
PTC of this series, p27Kip1 protein status was classi-
fied as low (p27Kip1 protein nuclear staining in
<24.8% of tumor cells) or high (p27Kip1 protein nu-
clear staining in 24.8% tumor cells).
DNA Extraction and Analysis
The DNA material was retrieved from paraffin blocks
after careful microdissection performed by an experi-
enced pathologist (A.M.). For tumors measuring <4
mm, DNA extraction was performed by using a laser
pressure catapulting (LPC) laser microdissection sys-
tem, based on a Zeiss inverted microscope PALM
Laser Micro-Beam System UV laser at 337 nm (Carl
Zeiss AG, Oberkochen, Germany), linked to a perso-
nal computer with the required software programs as
previously described.12 Genomic DNA was extracted
by using the QIAamp Tissue Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol.
BRAFV600E mutation was detected by a real-time, al-
lele-specific amplification essentially as described by
Jarry et al.13 Briefly, polymerase chain reaction (PCR)
amplifications were performed by using QuantiTect
SybrGreen PCR kit (Qiagen). The reaction mixture
contained 5 lL of the supplied 23 master mix, 0.4 lL
of each primer (0.4 lM each), and PCR-grade water
to a volume of 7.9 lL. Capillaries were loaded with
7.9 lL of this master mix, and 2.1 lL of the extracted
DNA template was added. Amplification was per-
formed with a Lightcycler (Roche Diagnostics GmbH,
Mannheim, Germany), and fluorescence was meas-
ured into the F1 channel. The cycling conditions
were as follows: denaturation for 15 minutes at 958C;
amplification for 45 cycles, with denaturation for 10
seconds at 958C; annealing for 5 seconds at 558C,
and extension for 10 seconds at 728C with fluores-
cence acquisition; holding step for 20 seconds at
728C. After completion of the cycling process, sam-
ples were subjected to melting curve analysis. Briefly,
samples were slowly cooled (0.18C/second) to 508C
for 30 seconds and then to a temperature ramp from
50 to 90C8 at 0.18C/second with continuous fluores-
cence monitoring. For each sample, the 2dF1/dT
versus T plot was displayed, and a single narrow
peak was obtained, indicating specific amplification
without significant by-products. Positive results were
further confirmed by using the B-RAF Mutector kit
(Trimgen; Tebu-Bio, Milan, Italy) and following the
manufacturer’s protocol. Randomly selected mutated
(n 5 5) and wild-type (n 5 5) cases (as confirmed by
Mutector assay) were further sequenced by the pri-
mers described by Davis et al.,4 with the use of the
ABI BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, Calif) and subjected
to automatic sequencing by using ABI Prism 310
Genetic Analyzer (Applied Biosystems) (data not
shown).
For multifocal tumors and multiple LN metasta-
ses, BRAFV600E mutation was detected on all lesions;
if any of the tumor foci was BRAFV600E positive, the
case was included in the ‘‘mutated’’ group.
Statistical Methods
Continuous variables were analyzed as mean values
plus or minus a standard deviation. Rates and pro-
portions were calculated for categorical data. For cat-
egorical variables, differences were analyzed by
means of the chi-square test and Fisher exact test
when appropriate. As continuous variables were
without normal distribution, we used nonparametric
tests, and differences were analyzed by the Mann-
Whitney U test. The differences between paired con-
tinuous variables were analyzed by means of the Wil-
coxon test. Correlations among continuous variables
were determined by using the Spearman test, the
nonparametric equivalent for the Pearson test.
P < .05 was considered statistically significant. All
analyses were performed with SPSS software (2001
release 11.0; Chicago, Ill).
RESULTS
Clinicopathological characteristics of the 214 PTC 1
cm included in this study are shown in Table 1. An
examination of the distribution of tumors without
LN metastases (Group I) and with LN metastases
(Group II), showed significant differences, apart from
clinical signs, among intraglandular multifocality,
bilaterality, sclerosis, BRAFV600E mutation, and
p27Kip1 protein expression.
BRAFV600E mutation was detected in 88 (41%) of
the tumors examined (Fig. 1); sequencing confirmed
the allele-specific and the Mutector analysis. An ex-
amination of the distribution of tumors with and
those without BRAFV600E mutation showed no signifi-
cant differences in clinical signs, sex, maximum di-
ameter of the primary lesion, vascular invasion,
grade of sclerosis, degree of encapsulation, multifo-
cality, bilaterality, extrathyroidal extension, or p27Kip1
protein expression (data not shown). Statistical anal-
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ysis, however, demonstrated a significant association
between age of patients and BRAFV600E mutation.
The mean age of the patients with BRAFV600E muta-
tion was significantly higher than that of patients
without BRAFV600E mutation (52.7  2.9 years vs
33.4  2.3 years; P < .001).
In addition to LN metastasis, low p27Kip1 protein
expression was significantly associated with multifocal-
ity, bilaterality, and extrathyroidal extension (Table 2).
BRAFV600E Mutation and p27Kip1 Expression in
LN Metastases
Of the 42 cases in Group II, 22 were classified as
pN1a and 20 as pN1b; 22 cases showed metastatic
lesions with an extracapsular extension of the lymph
node (ECE-LN).
Twenty-three of 42 harbored the BRAFV600E
mutation in primary PTC 1 cm, and 17 of 23 (74%)
also presented the same mutation in their respective
LNs. All the remaining 6 cases with BRAFV600E muta-
tion in primary tumors with no mutation in LNs had
multiple foci of PTC 1 cm in the thyroid gland with
BRAFV600E-positive and BRAFV600E-negative tumors
coexisting in the same patient. Nineteen cases did
not harbor the BRAFV600E in the primary PTC, and of
these, 13 cases did not show the BRAFV600E mutation
in their respective LNs, whereas the other 6 showed
the BRAFV600E mutation in the LN metastasized tu-
mor tissue.
We observed that metastasized LNs harboring
the BRAFV600E mutation presented a wider diameter
of the largest metastatic area, a higher number of
involved metastatic LNs, and a higher percentage
of ECE-LN in comparison with LNs without muta-
tions. No difference was found in BRAFV600E with
regard to compartment involvement (N1a or N1b)
(Table 3).
An evaluation of p27Kip1 expression in LN metas-
tasized tumor cells showed a significantly lower
mean value than that observed in corresponding
primary PTC (5.77  6.14% vs 14.27  18.24%;
P 5 .006). Furthermore, whereas 36 (86%) tumors
showed low p27Kip1 protein expression (labeling
index <24.8%) in primary PTC, in all cases of LN
metastases, the p27Kip1 labeling index of cancer
cells was <24.8%. The lowest mean value of p27Kip1
labeling index was detected in ECE-LNs when com-
pared with LNs without ECE (1.78  2.19% vs
10.16  6.11%; P < .001). No difference was found in
p27Kip1 protein expression in relation to compart-
ment involvement (N1a or N1b [7.73  7.17% vs
3.61  3.89%; P 5 .068]), whereas an inverse correla-
tion was found between the p27Kip1 labeling index
and the number of metastatic LNs (Rho 20.659;
P < .001), as well as between the p27Kip1 labeling
index and the diameter of largest metastatic area in
LN (Rho 20.732; P < .001) (Fig. 2).
With regard to p27Kip1 protein expression and
BRAFV600E, we found a significant lower mean value
of p27Kip1 labeling index in LNs harboring the
BRAFV600E mutation in comparison with those with-
out the mutation (1.87  2.44% vs 10.49  5.97%;
P < .001) (Fig. 3).
By applying an arbitrary score analysis on the
basis of the number of metastasized LNs >3, the
presence of ECE-LNs, and the diameter of the largest
metastatic area >3 cm (score 0 5 none of the
selected evaluation criteria present; 1 5 1 single cri-
TABLE 1
Comparison of Clinicopathological Parameters in Nonmetastatic
(Group I) and Metastatic (Group II) Papillary Thyroid Carcinomas
≤1 cm
Parameters
Group I
Node2 (%) n 5 172
Group II
Node1 (%) n 5 42 P*
Clinical signs
Nonincidental (48) 83 (86) 36
Incidental (52) 89 (14) 6 <.001
Age, y
<45 (46) 79 (55) 23
45 (54) 93 (45) 19 NS
Sex
Women (82) 141 (71) 30
Men (18) 31 (29) 12 NS
Maximum diameter of primary lesion
<5mm (43) 74 (43) 18
5mm (57) 98 (57) 24 NS
Intraglandular multifocality
Present (26) 45 (76) 32 <.001
Bilaterality
Present (3) 6 (71) 30 <.001
Extrathyroidal extension
Present (15) 26 (17) 7 NS
Vascular invasion
Present (5) 9 (7) 3 NS
Grade of sclerosis
Sclerosing (1) 1 (12) 5
Nonsclerosing (99) 171 (88) 37 <.001
Degree of encapsulation
Encapsulated (52) 89 (55) 23
Nonencapsulated (48) 83 (45) 19 NS
BRAFV600E
Wild-type (62) 107 (45) 19
Mutant (38) 65 (55) 23 .034
P27Kip1 protein expression
LI 24.8% (87) 150 (14) 6
LI <24.8% (13) 22 (86) 36 <.001
NS indicates not significant; LI, labeling index.
* Chi-square test and Fisher exact test; statistical results were considered significant for
P values <.05.
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terion; 2 5 2 criteria present; 3 5 all 3 selected crite-
ria present) and then subdividing the 42 patients
with LN metastases, we found that BRAFV600E muta-
tion was found in 11 of 12 (92%) patients belonging
to score 3, in 50% of patients belonging to score 1
and to score 2, and in 1 of 8 (12.5%) patients with
score 0; these differences proved to be significant
(P < .001). When we analyzed p27Kip1 protein expres-
sion, we found that the progressive reduction of
p27Kip1 labeling index was significantly associated
with the worst score (Fig. 4).
Moreover, we also investigated possible associa-
tions between the clinicopathological features of the
primary tumors with LN metastasis (Group II) and
our arbitrary score; the only parameter significantly
associated (P 5 .044) was the mean value of p27Kip1
labeling index of primary tumors with LN metastasis
in score 0 (27.68%  16.24%) versus mean value of
p27Kip1 labeling index of primary tumors with LN
metastasis in score 3 (11.32%  9.44%).
FIGURE 1. Representative cases of PTC with (A) wild-type or (C) BRAFV600E mutation and with (B) high expression or (D) low expression of p27Kip1.
TABLE 2
Low p27Kip1 Protein Expression (LI <24.8%) and Lymph Node Status,
Intraglandular Multifocality, Bilaterality, Extrathyroidal Invasion in
214 Patients With PTC 1 cm
Parameters Total
Low p27Kip1 protein
expression, no. (%) P*
Node
Node2 172 22 (13)
Node1 42 36 (86) <.001
Intraglandular multifocality
Absent 137 18 (14)
Present 77 40 (52) <.001
Bilaterality
Absent 178 25 (14)
Present 36 33 (92) <.001
Extrathyroidal invasion
Absent 181 27 (15)
Present 33 31 (94) <.001
LI indicates labeling index.
* Chi-square test; statistical results were considered significant for P values <.05.
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DISCUSSION
Several studies have investigated the role of the
BRAFV600E mutation in PTC24–30, and several of
them,17,18 though not all,16,20 have reported a signifi-
cant association of this mutation with metastasis and
local invasion. These differences may be explained
by the low number of cases composing the
cohort16,20 and the different histotype composition of
the PTC,20 which may obscure the association
between some poor clinicopathological outcomes
and BRAFV600E mutation; several studies, however,
have reported BRAFV600E mutation at a higher rate in
PTC with invasive and metastatic potential than in
noninvasive tumors, although without statistical sig-
nificance.16
In our own study, the BRAFV600E mutation in pri-
mary tumors was associated with LN metastases. In
concordance with other authors,16,18,21 we also
observed that patients with PTC lesions harboring
the BRAFV600E mutation were older in age than those
presenting PTC lesions with wild-type BRAF. The
higher age of patients with conventional PTC dis-
playing BRAFV600E may indicate either that tumors
with the mutation start their neoplastic develop-
ment (initiation and/or early phase of promotion)
in older individuals or, having started in a similar
age period, progress more slowly than PTC without
the mutation.
FIGURE 2. Bivariate scatter plot of p27Kip1 labeling index and diameter
(cm) of largest metastatic area in lymph nodes. Correlations among continu-
ous variables and P values were determined by using the Spearman test;
statistical results were considered significant for P values <.05.
TABLE 3
Features of 42 Metastasized Lymph Nodes in Relation to BRAF
Features
BRAF Wild-type
(n 5 19)
BRAFV600E
Mutant (n 5 23) P
Largest metastatic area diameter,
cm, Mean  SD 1.79  0.78 3.06  0.47 <.001*
No. metastatic lymph nodes,
Mean  SD 2.47  1.3 4.13  1.18 <.001*
Extracapsular extension of
lymph nodes, No. (%) 5 (26) 17 (74) .003
y
Node
pN1a, No. (%) 13 (68) 9 (39)
pN1b, No. (%) 6 (32) 14 (61) .059y
SD indicates standard deviation (standard error of the mean).
* Mann-Whitney test; significant values when P < .05.
y Chi-square test; significant values when P < .05.
FIGURE 3. p27Kip1 labeling index in comparison with BRAFV600E in lymph
node metastases. A lower p27Kip1 protein expression was observed in LNs
harboring the BRAFV600E mutation in comparison with those without the
mutation (1.87  2.44% vs 10.49  5.97%; P < .001). Differences were
analyzed by the Mann-Whitney test; statistical results were considered sig-
nificant for P values <.05.
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In our series, 6 cases with multiple foci of
tumors with BRAFV600E-positive and BRAFV600E-nega-
tive tumors coexisted in the same patient not pre-
senting the BRAFV600E mutation in their respective
LN metastases, and 6 out of 19 cases did not harbor
the BRAFV600E in the primary PTC harboring the
BRAFV600E mutation in their respective LNs. It is,
therefore, possible that the BRAF mutation is not
absolutely essential for the metastasis of PTC 1cm
to LNs; this would be consistent with other clinico-
pathological studies reporting the association of both
BRAF mutation-positive and mutation-negative pri-
mary PTC tumors with LN metastases.16–18,20,22
Moreover, recent studies have reported novel BRAF
mutations only in LN-metastasized PTC and not in
the primary tumors.23,24 The high prevalence of the
BRAF mutation in LN-metastasized thyroid tumors in
cases showing this mutation in their primary tumors
supports the notion that the BRAF mutation may
facilitate the seeding and progression of PTC cells in
LNs, consistent with the finding that the mutation is
associated with a higher prevalence of LN metastasis
of PTC.25
In the present study, the low p27Kip1 protein
expression was strongly associated with LN metas-
tases; we also found a significant association
between low p27Kip1 protein expression and multi-
focality, bilaterality, and extrathyroidal extension.
These findings are in line with previous studies on
p27Kip1 protein expression in thyroid papillary
microcarcinomas.26,27
Previous studies have not, however, included an
examination of p27Kip1 expression in LN metastases
and paired PTCs. It should be noted that we our-
selves have evaluated the potential role of p27Kip1
in the process of LN metastasis. The levels of
p27Kip1 expression in primary PTCs were found to
be higher than those of compared LN metastases.
Recent studies have revealed a significant reduction
in the expression of p27Kip1 in the metastatic site
compared with that detected in the corresponding
primary tumors; p27 has also been shown to have a
function in adhesion-dependent cell growth.5 In our
own study, the lowest mean value of p27Kip1 label-
ing index was detected in ECE-LNs when compared
with LNs without ECE, and, in our arbitrary score,
the progressive reduction of p27Kip1 labeling index
was significantly associated with the worst score.
With regard to the pathological characteristics
of LN-metastasized tumor cells, we found a signifi-
FIGURE 4. p27Kip1 labeling index and BRAFV600E mutation in 42 cases of lymph node metastases were subdivided according to our scores. The progressive
reduction of p27Kip1 protein expression in metastatic lymph node tumor cells was significantly associated with the worst score (score 0 vs score 2, P 5 .004;
score 0 vs score 3 P < .001; P values were determined by using Kruskal Wallis test.) BRAFV600E mutation in metastatic lymph node tumor cells was found in
92% (11 of 12) of cases belonging to score 3, in 50% of cases belonging to score 1 and to score 2, and in 12.5% cases with score 0; these differences
proved to be significant (P < .001); P values were calculated by using the chi-square and Fisher exact tests. Statistical results were considered significant for
P values <.05.
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cant lower mean value of p27Kip1 labeling index in
LNs harboring the BRAFV600E mutation in compari-
son with those without the mutation. The level of
the p27Kip1 protein is mainly regulated by post-
translational mechanisms through degradation by
ubiquitin-dependent proteolysis.28 A recent study
on melanoma cells shows that mutation of BRAF
subverts adhesion control of the extracellular sig-
nal-regulated kinases 1 and 2 (ERK1/2) pathway
leading to deregulation of cyclin D1 and p27Kip1
levels.29
In conclusion, as far as we know, the present
study is the first analysis of both BRAFV600E muta-
tion and p27Kip1 protein expression in primary PTC
1 cm and their paired LN metastases, suggesting
that BRAFV600E mutation and down-regulation of
p27Kip1 in cancer cells of PTC 1 cm may be con-
sidered as factors facilitating tumor-cell growth and
progression, once these are seeded in the LNs.
Although they do not provide direct experimental
evidence that, as recently demonstrated in other
tumors,29,30 BRAFV600E mutation down-regulates
p27Kip1 expression in thyroid cancer cells, our find-
ings suggest an interplay between BRAFV600E muta-
tion and p27Kip1 underexpression. Further in vitro
experiments are needed to clarify these possible
molecular interactions.
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